All In Biotech

Drug Trial Radar · NCT06075953

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Feb 17, 2024

Primary completion

Nov 2028

Study completion Nov 2033

Sponsor

Lead sponsor
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Conditions

  • Ductal Carcinoma in Situ

Interventions

  • TamoxifenDrug

    For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose). For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

  • ExemestaneDrug

    For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally

  • LetrozoleDrug

    For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.

  • AnastrazoleDrug

    For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.

  • Testosterone + AnastrazoleDrug

    Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.

  • ElacestrantDrug

    Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.

  • Z-endoxifenDrug

    Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients remaining on active surveillance at 7 monthsTime frame: 7 months

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Berkeley Outpatient Center

    Berkeley, California · Recruiting

  • City of Hope -Duarte Cancer Center

    Duarte, California · Recruiting

  • City of Hope - Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • City of Hope

    South Pasadena, California · Recruiting

  • John Muir Health

    Walnut Creek, California · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Maple Grove Cancer Center

    Maple Grove, Minnesota · Recruiting

  • Hennepin Healthcare -Minneapolis

    Minneapolis, Minnesota · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Health Partners - Frauenshuh Cancer Center

    Saint Louis Park, Minnesota · Recruiting

  • Health Partners - Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • Englewood Hospital and Medical Center

    Englewood, New Jersey · Recruiting

  • Mount Sinai Union Square

    New York, New York · Recruiting

  • Mount Sinai Chelsea

    New York, New York · Recruiting

  • Mount Sinai West

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Montefiore Medical Center (Hutchinson Campus Tower 1)

    The Bronx, New York · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

  • Bryn Mawr Hospital

    Bryn Mawr, Pennsylvania · Active not recruiting

  • Paoli Hospital

    Paoli, Pennsylvania · Active not recruiting

  • Lankenau Medical Center

    Wynnewood, Pennsylvania · Active not recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.